### **Overview** Eiko Lifesciences Ltd. (ELL), formerly known as Narendra Investments (Delhi) Ltd., rebranded in June 2021 to reflect its strategic pivot into specialty and fine chemicals. Headquartered in India, the company operates as an integrated manufacturer, supplier, and exporter of high-value chemical products serving global markets in pharmaceuticals, agrochemicals, personal care, food additives, and electronics. Over the past few years, ELL has evolved from a niche chemical player into a diversified lifesciences and logistics enterprise, marked by aggressive diversification, strategic partnerships, and a strong focus on R&D and supply chain resilience. --- ### **Core Business Segments (as of March 31, 2025)** 1. **Agrochemicals** 2. **Oleo Chemicals** 3. **Pharmaceuticals** 4. **Food Additives** 5. **Clinical Research and Development** 6. **Logistics** All manufacturing is carried out at its state-of-the-art facility in **Badlapur, Maharashtra**, which began commercial operations in October 2020 and spans 41,920 sq. meters. The plant is equipped with stainless steel and glass-lined reactors, centrifuges, dryers, and auxiliary units (boilers, chilling plants, co-generation power plant, desalination, and effluent treatment), supporting high-temperature and high-pressure reactions required for complex organic synthesis. --- ### **Strategic Diversification & Expansion (2023–2025)** #### **1. Expansion into Oleochemicals (2024)** - In **September 2024**, ELL entered the **oleochemicals and allied business** through a strategic agreement with **Vivacious Pharmatex Pvt. Ltd. (VPPL)**. - ELL committed ₹8 crore over one year and became VPPL’s **preferred supplier of key raw materials**. - The partnership targets markets such as personal care, pharmaceuticals, agrochemicals, paints, coatings, and polymers. - VPPL supports ELL in **product development, commercialization, and marketing**, enabling faster market penetration. #### **2. Strategic Stake in Reflux Pharmaceuticals (2023)** - In **May 2023**, ELL acquired a **25.01% stake** in **Reflux Pharmaceuticals Private Limited (RPPL)**, a manufacturer of APIs and intermediates. - The collaboration includes **joint development, co-manufacturing, and co-marketing** of products such as Tolfenamic Acid, Flavoxate HCl, Diacerein, Albendazole, Carprofen, and Sulindac — targeting therapeutic areas like NSAIDs, anti-spasmodics, and anti-helminthics. - ELL supplies key raw materials to RPPL and leverages RPPL’s footprint for **entry into European markets**. #### **3. Entry into Logistics & Container Leasing (2024–2025)** - In **November 2024**, ELL launched **EikoVivify Logistics Private Limited (EVL)** as a **51:49 joint venture** with Vivify Wealth Management LLP, with a committed capital investment of ₹100 crores over three years. - EVL operates in **shipping container leasing, rental, management, and maintenance**, sourcing containers domestically and internationally. - Initial fleet: **over 800 TEUs**, later expanded to **approximately 1,000 containers** (including dry, flat rack, open-top, and refrigerated units). - In **December 2024**, EVL entered a **long-term agreement with S J Logistics (India) Ltd. (SJL)** — a listed SME with ₹1,000 crore market cap and global logistics experience — to supply **2,500 TEUs** over five years, generating an estimated **₹65 crores in revenue**. - The logistics arm is designed as an **asset-backed, income-stable business** that enhances both internal supply chain control and external revenue generation. #### **4. Launch of Clinical R&D & Innovation Venture (2025)** - In **July 2025**, ELL launched **Eiko Scientific Solutions LLP**, a wholly owned subsidiary focused on **R&D in specialty chemicals, healthcare innovation, diagnostics, and medical solutions**. - A **₹5 crore investment over three years** has been approved to support new science and technology initiatives in **regulated chemical and healthcare sectors**. - The venture also **imports and exports advanced technologies** for pharmaceutical and diagnostic applications, targeting high-growth verticals. - This positions ELL at the intersection of **chemical innovation and clinical development**, aligning with global healthcare trends. #### **5. Market Entry into Emollients & Pearling Agents (2023–2024)** - In **May 2023**, ELL commercially launched **Isopropyl Myristate and Isopropyl Palmitate**, specialty emollients used in cosmetics, perfumes, and skincare. - Products received **approvals from major international customers**; export discussions underway with global players. - Pipeline includes **Ethylene Glycol Di-stearate, Ethylene Glycol Monostearate (pearling agents), and MCT Oil**, expanding ELL’s footprint in the **cosmetics and personal care** sector. - In **December 2022**, ELL had already developed 10 emollient products (e.g., Isopropyl Oleate, Butyl Laurate) and initiated marketing in **India, Russia, and Bangladesh**. --- ### **R&D and Innovation** - ELL maintains a strong **in-house R&D focus**, developing niche molecules tailored to pharmaceutical, agrochemical, and fragrance industries. - Key capabilities include: - Process optimization and **cost reduction** via efficient catalysis, energy-saving techniques, and utility reduction. - **Backward and forward integration** to enhance margins and supply reliability. - **Flexible (fungible) manufacturing** to adapt production to market demand. - Strategic R&D partnerships include **Omkar Speciality Chemicals Ltd. (2020)** in quality management and marketing technology. - Entry into **fragrances & flavors (F&F)** was announced in **November 2020**, with **Coumarin and derivatives** as flagship products used in perfumes, food, and flavoring. --- ### **Key Products & Applications** | **Product** | **Application** | |------------|----------------| | 3-Chloropropiophenone | Intermediate for Bupropion (smoking cessation drug) | | Orthochlorobenzonitrile | Used in pharmaceuticals, pesticides; **only Indian manufacturer** | | Saccharin & Sodium Saccharin | Artificial sweeteners (food, beverages, medicines, agrochemicals) | | Diacerein, Sulindac, Carprofen | APIs for osteoarthritis, anti-inflammatory conditions | | Isopropyl Myristate/Palmitate | Emollients for cosmetics and perfumes | | Corrosion Inhibitors, Solvents, Photographic Chemicals | Industrial and agrochemical applications | | Halogenated Aromatic Compounds (bromo/chloro derivatives) | Critical in pharmaceutical synthesis | --- ### **Global Reach & Compliance** - ELL exports to **8+ countries**, including **Germany, Italy, Netherlands, and Israel** – all **regulated markets**, demonstrating adherence to international quality and compliance standards. - Manufacturing adheres to **strict QA/QC protocols**, with dedicated departments for assurance, regulatory compliance, and environmental safety (effluent treatment). - Strategic alliances (e.g., RPPL, VPPL, SJL) enhance market access and **backward integration**, supporting **entry into Europe** and long-term stability.